Kitchen, Scott G., Korin, Yael D., Roth, Michael D., Landay, Alan, Zack, Jerome A.
Human immunodeficiency virus type 1 (HIV-1) infection requires cell surface expression of CD4. Costimulation of CD8+/CD4− T lymphocytes by anti-CD3 and anti-CD28 antibodies or by allogeneic...
Kitchen, Scott G., Korin, Yael D., Roth, Michael D., Landay, Alan, Zack, Jerome A.
Human immunodeficiency virus type 1 (HIV-1) infection requires cell surface expression of CD4. Costimulation of CD8+/CD4− T lymphocytes by anti-CD3 and anti-CD28 antibodies or by allogeneic...
Khanna, Dinesh, Yan, Xiaohong, Tashkin, Donald P., Furst, Daniel E., Elashoff, Robert, Roth, Michael D., ...
Objective To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment. Methods One hundred fifty-eight...
Pharmacokinetics of a novel agent, R667, in patients with emphysema
Chiu, Yu-Yuan, Roth, Michael D, Kolis, Stanley, Rogovitz, David, Davies, Brian
Jewish youths at risk: A pilot study.
Thesis (Psy.D.)--Fairleigh Dickinson University, 2003.
Jewish youths at risk: A pilot study.
Thesis (Psy.D.)--Fairleigh Dickinson University, 2003.
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
Tashkin, Donald P., Elashoff, Robert, Clements, Philip J., Roth, Michael D., Furst, Daniel E., Silver, Richard M., ...
Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although treatment-related...